加载中
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
前收盘价
US$1.28
−US$0.05 · -3.76%
盘中时间采用ET。市场数据可能有所延迟。
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
日内区间
当前US$1.28
52周区间
当前US$1.28
盘中时间采用ET。市场数据可能有所延迟。
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
日内区间
当前US$1.28
52周区间
当前US$1.28
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 112.3万 USD | 4.3万 USD | — | — | — |
| 销货成本 | 32.7万 USD | — | — | — | — |
| 毛利 | 79.6万 USD | 4.3万 USD | — | — | — |
| 研究与开发 | 626.9万 USD | 602.5万 USD | 566.7万 USD | 430.1万 USD | 303.9万 USD |
| 销售、一般及管理费用 | 703.7万 USD | 498.8万 USD | 572.9万 USD | 564.9万 USD | 263.2万 USD |
| 营业费用 | 1330.6万 USD | 1101.3万 USD | 1139.6万 USD | 995万 USD | 567.1万 USD |
| 利息收入 | 42.7万 USD | 38.4万 USD | — | 5.7万 USD | 7万 USD |
| 利息支出 | — | — | 10.8万 USD | 5.7万 USD | 90.4万 USD |
| 折旧和摊销 | 2000 USD | — | 6000 USD | 6000 USD | 9000 USD |
| 营业利润 | −1251万 USD | −1097万 USD | −1139.6万 USD | −995万 USD | −567.1万 USD |
| 净利润 | −1116.8万 USD | −881.4万 USD | −1023.2万 USD | −988.9万 USD | −632.4万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
